Aurobindo Pharma Q2FY27 revenue reaches Rs 10,263 crore

Aurobindo Pharma Limited recorded its highest quarterly revenue of Rs 10,263 crore in Q2FY27, up 23.9% year on year, while earnings before interest, tax, depreciation and amortisation (EBITDA) rose 28.5% to Rs 2,156 crore and its EBITDA margin reached 21.0%.

What were Aurobindo Pharma's Q2FY27 sales and profits?

Aurobindo Pharma reported revenue from operations of Rs 10,263 crore in Q2FY27, compared with Rs 8,286 crore in Q2FY26 and Rs 9,150 crore in Q1FY27. Management described this as its highest-ever quarterly revenue, with sales rising 23.9% year on year and 12.2% quarter on quarter.

EBITDA before foreign-exchange movements and other income was Rs 2,156 crore, up from Rs 1,678 crore in Q2FY26 and Rs 1,881 crore in Q1FY27. Profit before tax increased 32.7% year on year to Rs 1,691 crore, while profit after tax increased 32.5% to Rs 1,124 crore.

Aurobindo Pharma reported net profit attributable to owners of Rs 1,126 crore, compared with Rs 848 crore a year earlier. Reported earnings per share were Rs 19.57 in Q2FY27, against Rs 14.61 in Q2FY26 and Rs 17.86 in Q1FY27; the presentation recorded minority interest of Rs 2 crore in the latest quarter.

Which businesses drove Aurobindo Pharma's revenue growth?

Aurobindo Pharma's formulations revenue rose 24.2% year on year to Rs 9,102 crore in Q2FY27, while active pharmaceutical ingredient (API) revenue rose 20.9% to Rs 1,162 crore. Formulations were also 12.4% above Q1FY27 revenue of Rs 8,101 crore, and API revenue was 10.7% above Rs 1,049 crore in the preceding quarter.

The United States was the largest disclosed market at Rs 4,555 crore, up 25.2% from Rs 3,638 crore in Q2FY26 and 20.8% from Rs 3,770 crore in Q1FY27. The US accounted for 44% of consolidated revenue, and management attributed growth excluding gRevlimid to Lannett integration, volume gains and an injectables ramp-up.

Europe delivered Rs 3,161 crore, rising 27.5% year on year and 7.6% quarter on quarter. Growth Markets generated Rs 1,026 crore, up 16.3% year on year but down 3.5% from Q1FY27, while antiretroviral revenue was Rs 359 crore, up 10.2% year on year and 8.7% sequentially; management linked antiretroviral variation to tender opportunities.

Within API, beta-lactam revenue increased 24.8% year on year to Rs 858 crore, ahead of the 11.3% increase in non-beta-lactam revenue to Rs 304 crore. Non-beta-lactam revenue grew 21.7% quarter on quarter, compared with 7.3% for beta-lactam, and management said the API increase reflected performance across the portfolio.

How did Aurobindo Pharma's profitability change?

Aurobindo Pharma's EBITDA margin rose to 21.0% in Q2FY27 from 20.3% in Q2FY26 and 20.6% in Q1FY27. The 75-basis-point year-on-year improvement accompanied a 26.9% increase in gross profit to Rs 6,280 crore, compared with revenue growth of 23.9%; one basis point equals one-hundredth of a percentage point.

Gross margin reached 61.2%, compared with 59.7% a year earlier and 60.4% in Q1FY27. Overheads increased 26.2% year on year to Rs 4,124 crore, while EBITDA increased by Rs 478 crore from Q2FY26, exceeding the Rs 275 crore sequential increase from Q1FY27.

Below EBITDA, depreciation rose 23.8% year on year to Rs 531 crore and finance cost increased 7.3% to Rs 102 crore. Other income rose 43.0% to Rs 165 crore, foreign-exchange gain was Rs 3 crore versus Rs 5 crore in Q2FY26, and tax increased 31.8% to Rs 564 crore.

What was Aurobindo Pharma's cash and debt position?

Aurobindo Pharma reported net cash including investments of Rs 1,812 crore at September 2026, compared with net cash of Rs 3,002 crore at March 2026. Cash balances and investments were Rs 10,044 crore at September 2026, exceeding gross debt of Rs 8,232 crore.

Gross debt increased from Rs 7,673 crore at March 2026 to Rs 8,232 crore at September 2026. Foreign-currency loans restated in rupees rose to Rs 7,628 crore from Rs 6,709 crore, while rupee loans fell to Rs 604 crore from Rs 964 crore over the same period.

The presentation showed cash flow from business of Rs 188 crore in its reported foreign-currency presentation for Q2FY27, before strategic capital expenditure and dividends. Management also reported a closing net-cash position including investments at September 2026, despite completing the Lannett acquisition and undertaking capital expenditure during the quarter.

What operating milestones did Aurobindo Pharma disclose?

Aurobindo Pharma completed the Lannett acquisition in Q2FY27, which management said expanded its US capabilities in complex and controlled substances. The company launched 10 US products, including gAdvair and ADQUEY, its first new chemical entity, and received final approval for 12 products during the quarter, including one previously tentatively approved product.

Aurobindo Pharma is adding 10,000 litres of mammalian cell-culture bioreactor capacity through four 2,500-litre units with integrated purification suites. Management said the Aurovaccines merger was on track for a 2027 target completion, with the repurposed facility expected to add microbial and mammalian drug-substance capacity, as well as pre-filled syringe and vial filling lines, by end-2027.

The disclosed biosimilar plan includes a US Food and Drug Administration filing for OMAZIJEV in the current financial year following its filing with the European Medicines Agency. Beqvola, authorised in India, is scheduled for launch next quarter; first supplies of CAVOLEY and NUGEFY European brands are also due next quarter, while trastuzumab subcutaneous formulation is planned to enter clinical studies in December 2026.

Conclusion

Aurobindo Pharma combined record Q2FY27 revenue of Rs 10,263 crore with EBITDA growth of 28.5% and a 21.0% EBITDA margin. Formulations contributed Rs 9,102 crore and API contributed Rs 1,162 crore, while the US and Europe each recorded year-on-year growth above 25%.

The next disclosed milestones are the planned OMAZIJEV US filing in the current financial year, Beqvola's India launch and European product supplies next quarter, and capacity additions targeted by end-2027. Aurobindo Pharma's September 2026 net cash including investments of Rs 1,812 crore will remain relevant as it funds product development, biologics capacity and other capital expenditure.